Essential Pharma Acquires HALDOL Rights from Janssen Pharmaceutica NV
December 7, 2022
Gyrus Capital-backed Essential Pharma has acquired global rights to HALDOL (haloperidol) and HALDOL Decanoate from Janssen Pharmaceutica NV. The deal expands Essential Pharma's specialty CNS portfolio and secures continued global supply of this WHO-listed essential antipsychotic marketed in the US and more than 60 countries.
- Buyers
- Essential Pharma, Gyrus Capital
- Targets
- HALDOL (haloperidol), HALDOL Decanoate (haloperidol decanoate)
- Sellers
- Janssen Pharmaceutica NV
- Industry
- Pharmaceuticals
- Location
- Antwerp, Belgium
- Transaction Type
- Divestiture
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.